MedTrace Logo

Comparison of Citrate and Heparin Anticoagulation During Hemodialysis With MCO PES-PVP (Theranova) Membrane

NCT04139525 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2022-06-07

No results posted yet for this study

Summary

The purpose of the study is to compare the efficiency and biocompatibility of citrate and heparin anticoagulation during hemodialysis with medium cut-off polyarylethersulphone-polyvinylpirrolidone membrane (Theranova®).

Conditions

Interventions

BIOLOGICAL

unfractionated heparin

A bolus of 30 I.U./kg at the start of hemodialysis, followed by 18 I.U./kg per every hour of hemodialysis.

BIOLOGICAL

8% trisodium citrate

8% trisodium citrate in the dose of 150 ml/h.

Sponsors & Collaborators

  • Marija Malgaj Vrečko

    lead OTHER

Principal Investigators

  • Marija Malgaj Vrečko, MD · University Medical Centre Ljubljana

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04139525 on ClinicalTrials.gov